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Abstract: Foot and mouth disease is a livestock acute disease, causing economic losses in affected
areas. Currently, control of this disease is performed by mandatory vaccination campaigns using
inactivated viral vaccines. In this work, we describe the development of a chimeric VLP-based
vaccine candidate for foot-and-mouth disease virus (FMDV), based on the co-expression of the HIV-1
Gag protein and a novel fusion rabies glycoprotein (RVG), which carries in its N-term the FMDV main
antigen: the G-H loop. It is demonstrated by confocal microscopy that both Gag-GFP polyprotein
and the G-H loop colocalize at the cell membrane and, that the Gag polyprotein of the HIV virus
acts as a scaffold for enveloped VLPs that during the budding process acquires the proteins that are
being expressed in the cell membrane. The obtained VLPs were spherical particles of 130 ± 40 nm in
diameter (analyzed by TEM, Cryo-TEM and NTA) carrying an envelope membrane that efficiently
display the GH-RVG on its surface (analyzed by gold immunolabeling). Immunostainings with a
FMDV hyperimmune serum showed that the heterologous antigenic site, genetically fused to RVG,
is recognized by specific G-H loop antibodies. Additionally, the cVLPs produced expose the G-H
loop to the liquid surrounding (analyzed by specific ELISA). Finally, we confirmed that these FMD
cVLPs are able to induce a specific humoral immune response, based on antibodies directed to the
G-H loop in experimental animals.
Keywords: virus-like particles; rabies; foot-and-mouth disease; HIV-1; chimeric; vaccine
1. Introduction
Foot and Mouth Disease (FMD) is a livestock viral acute disease-causing important
economic loss due to animal products trade restrictions and reduced productivity on
affected countries. It is caused by a highly infectious and antigenically variable virus
called Foot-and-Mouth Disease Virus (FMDV), member of the Picornaviridae family and
Apthovirus genus. Its genome consists of a single-stranded RNA of positive polarity that
encodes a polyprotein that is self-cleaved by a protease (3Cpro) giving rise to structural
and non-structural proteins [1]. The capsid proteins VP1–4 assemble in capsomers forming
a non-enveloped icosahedral particle. The most important antigenic site is an extremely
flexible loop region named G-H loop, located on amino acids (AA) 140–160 of VP1 [2]. It is
also the most variable region between different serotypes, with the exception of a highly
conserved RGD motif known to interact with host cell integrins and responsible for virus
entry into the cell [3]. To date, seven serotypes (A, O, C, Asia-1, SAT1, SAT2 and SAT3) and
multiple subtypes have been reported (Diaz-San Segundo et al, 2017).
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Several measures are taken to control FMD in endemic areas, relying on high surveil-
lance and massive vaccination of livestock, as well as strict control of animal movement
in and out of monitored areas [4]. The implementation of massive vaccination was a key
measure to eradicate the disease in affected countries of South America, and to control
possible outbreaks. Currently used vaccines consist of inactivated FMDV formulated with
various adjuvants, usually containing two or more serotypes or subtypes (Cao et al, 2016).
Despite their efficacy to control the disease, this type of vaccines has several disadvantages:
they require high biosafety environments for their production due to the fact that infective
virus must be manipulated, they do not provide long term protection, require multiple
doses, and must be maintained in cold chain as viral particles are thermo labile, having
short shelf-life [5].
Lots of efforts are being directed to develop new generation vaccines that solve
the difficulties previously mentioned, mostly toward subunit vaccines [5–7]. Virus-like
particles (VLPs) are a very promising technology in that field, being supramacromolecular
arrangements of viral proteins that mimic very closely the structure of the virus but lack
the viral genome, making them biologically safe. They are highly immunogenic because
of their particulated and highly multivalent nature, and can be obtained in a variety of
expression systems as bacterial, yeast, plant, as well as insect and mammalian cells [8–11].
FMDV empty capsids are normally observed in vivo during infection and have been
obtained by recombinant expression of FMDV polyprotein P1-2A and 3Cpro using the
baculovirus-insect cell system and insect larvae, as well as in viral vectored vaccines and
mammalian expression systems. These particles have proven to be effective at preventing
animals from developing clinical symptoms upon FMDV exposure, with different degrees
of protection [12]. Despite the protection induced in experimentation animals, recent
studies on the immune response triggered by these particles have concluded that capsid
integrity plays a key role in the development of a potent immune response in cattle [13],
which is problematic for certain serotypes known to have less stable capsids [14]. On the
other hand, recombinant empty capsid production is problematic because 3Cpro is toxic to
the host cell and as these particles are not secreted, a cell disruption step must be added to
the bioprocess [12]. These problems have been impairing the application of this technology
to a larger production scale.
The Gag polyprotein from the HIV virus is able to self-assemble into particles without
the need of any other viral protein. It accumulates at the vicinity of the producer cell
membrane and buds taking part of the lipidic cell membrane and the proteins that are
expressed at its surface [15]. The transient gene expression (TGE) of this protein, in
mammalian cell lines using serum-free media, have been widely explored as an interesting
platform for the production of biosafe vaccine candidates [16–20].
In this work, we designed a fusion protein based on the rabies virus (RV) glycopro-
tein and the FMDV G-H loop, to be co-expressed with the HIV-1 Gag capsid protein to
express a chimeric VLP (cVLP) as a novel vaccine candidate for FMD. The Gag gene was
fused in frame to the enhanced GFP gene, which allows for easy quantification of VLPs
using fluorometry and nanoparticle tracking analysis (NTA) techniques and also facilitates
characterization during process development. These functionalized Gag-based VLPs were
completely characterized and the humoral immune response triggered in mice was studied.
2. Materials and Methods
2.1. Fusion Protein Construction. Plasmids
The pGag-EGFP plasmid used, codes for a Rev independent HIV-1 Gag protein fused
in frame to the enhanced GFP (Hermida-Matsumoto and Resh, 2000). The plasmid from the
NIH AIDS Reagent Program (Cat 11468) was constructed by cloning the Gag sequence from
pCMV55M1–10 (Schwartz et al, 1992) into the pEGFP-N1 plasmid (Clonthec, Mountain
View, CA).
The coding sequence for the GH-RVG fusion protein was constructed inserting the
G-H loop 63 bp sequence of FMDV A/Arg/2001 strain, between the RV signal peptide and
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the N-term extreme of the glycoprotein. This 1650 bp fragment was then cloned in pCiNeo
expression vector (Promega, Madison, WI, USA), obtaining the pCiNeo- GH-RVG fusion
protein plasmid.
2.2. Cell Line, Media, and Culture Conditions
The HEK293 cell line provided by Dr. Amine Kamen from McGill University (Mon-
treal, Canada) derives from a cGMP master cell bank that is available for manufacturing of
clinical material. It is adapted to grow in suspension and in serum free medium. Cells were
cultured in Freestyle 293 medium (Invitrogen, Carlsbad, CA, USA) supplemented with
0.1% Pluronic®(Invitrogen, Carlsbad, CA, USA). Medium was also supplemented with 1.6
mg/L of r-transferrin (Merck Millipore, Kankakee, IL, USA), 19.8 mg/L of r-insulin (FeF
Chemicals/Novo Nordisk, Køge, Denmark.), and 0.9X of an in-house lipid mixture [21].
Cells were routinely maintained in 125-mL disposable polycarbonate Erlenmeyer flasks
(Corning, Steuben, NY, USA) in 20 mL of culture medium, shaken at 110 rpm using an
orbital shaker (Stuart, Stone, UK) placed in an incubator maintained at 37 ◦C in a hu-
midified atmosphere of 5% CO2 in air. Cell count and viability were determined using
NucleoCounter NC-3000 (ChemoMetec, Allerod, Denmark).
2.3. Transient Transfection
HEK293 cells were seeded at 0.5 × 106 cells/mL, allowed to grow for two days
until they reached 2 × 106 cells/mL and were transiently transfected using 25-kDa linear
polyethyleneimine (PEI) (PolySciences, Warrington, PA). Transfections were performed
using a final DNA concentration of 1 ug/mL of medium. PEI/DNA polyplexes were
formed by adding PEI to plasmid DNA (in a ratio 2:1) diluted in fresh culture media.
Complexes were incubated for 15 min at room temperature (RT) and added to the culture.
When production enhancers were studied, valproic acid (3.36 mM) and caffeine (5.04
mM) were added to cell culture 4 hours post transfection (hpt). For analysis, transfected
cells or culture medium containing VLPs were harvested at 24–96 hpt, depending on the
experiment.
2.4. VLP Purification
24–96 hpt culture was harvested, centrifuged at 300× g for 10 min to remove cells
and then at 10,000× g for 10 min to remove any remaining cellular debris. The clarified
supernatant was layered over a 30% sucrose cushion and centrifuged at 100,000 g for 3 h at
4 ◦C (Beckman SW32 rotor, Beckman L100XP, Beckman Coulter, USA). The supernatant
and sucrose cushion were poured off and the pellet was resuspended in PBS.
2.5. Confocal Microscopy
To analyze the expression of recombinant fusion proteins, 48-72 hpt freshly harvested
cells were pelleted by centrifugation, resuspended in PBS and incubated for 30 min at RT
with an in-house developed RVG specific monoclonal antibody [22] (diluted 1:1000 in PBS)
or, alternatively, with a polyclonal antibody raised against FMDV, obtained immunizing
rabbits with a commercial FMDV vaccine (Bioaftogen®, Biogénesis Bago, Argentina).
Cells were washed (PBS), followed by 30 min incubation at RT with an AlexaFluor647®
conjugated anti-mouse or anti-rabbit antibody, respectively (Thermo Fischer Scientific,
Waltham, MA, USA) diluted 1:000 in PBS). After that, cells were washed (PBS) and stained
with Hoeschst and CellMaskTM (Thermo Fischer Scientific, Waltham, MA, USA) for 10
min at RT. After another wash, cells were resuspended in fresh FreeStyle 293 cell culture
medium.
2.5.1. Standard Confocal Laser Scanning Microscopy (CLSM)
Visualization of VLP producer cells was performed by Fluoview® FV100 confocal
microscope (Olympus, Tokyo, Japan). The excitation/emission parameters of each dye
used for Confocal Microscopy were 633 nm/649 to 785 nm for Cell MaskTM, 405 nm/415
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to 480 nm for Hoechst, 561 nm/580 to 630 nm for AlexaFluor647® and 488 nm/500 to 560
nm for Gag-GFP VLPs. Samples were placed in glass bottom dishes (MatTek, Boston, MA)
for visualization under the microscope. Final images were processed using LAS AFTM
software (Leica Microsystems, Weztlar, Germany).
2.5.2. Super-Resolution Fluorescence Microscopy (SRFM)
SRFM analysis was performed using TCS SP8 confocal microscope equipped with
Huygens deconvolution suite and GPU arrays (Leica Microsystems, Wetzlar, Germany) at
Servei d’Anatomia Patològica from Hospital Sant Joan de Déu (Esplugues de Llobregat,
Barcelona, Spain). VLPs were imaged with HC PL APO CS2 100x/1.40 OIL objective
(zoom 5) with HyVolution2 (Lightning) mode (Leica Microsystems), 496 × 496–633 Hrz
speed and line average of 3. 488 nm (Gag-eGFP VLPs) and 568 nm (mAB) laser lines and
HyD detectors with BrightR mode (500–570 nm and 580–794 nm, respectively) were used.
HyVolution2 deconvolution was performed with SVI Huygens Professional software using
the best resolution strategy (Scientific Volume Imaging, Hilversum, The Netherlands).
2.6. Flow Cytometry
Transfected cells were fixed in 4% paraformaldehyde and then incubated for 30 min at
RT with an in-house RVG protein specific monoclonal antibody (diluted 1:1000 in PBS) [22].
Cells were washed with PBS, followed by 30 min incubation at RT with an AlexaFluor647®
conjugated goat anti-mouse antibody (Thermo Fischer Scientific, Waltham, MA, USA)
diluted 1:000 in PBS). Cells were washed and resuspended in PBS for flow cytometry
analysis using a BD FACS Canto flow cytometer (BD Biosciences, San Jose, CA, USA).
2.7. VLPs Analysis and Quantitation
2.7.1. Bi-specific” Sandwich ELISA
96-well microplates (Greiner Bio-one, Kremsmünster, Austria) were coated with 100 µL
of a 1:1000 dilution of a rabbit anti-FMDV serum in carbonate buffer pH 9.6 for 1 h at
37 ◦C and overnight at 4 ◦C. Plates were washed six times with PBS-Tween-20 0.05% and
then blocked with 200 µL per well of 2% skim milk in PBS for 1 h at 37 ◦C. Two-fold
serial dilutions of concentrated cVLP samples in skim milk 0.2%-PBS tween-20 0.05% were
incubated for 1 h at 37 ◦C. After that, 100 µL of a 1:2000 diluted biotynilated rabbit anti-RVG
serum in skim milk 0.2%-PBS tween-20 0.05% was added to each well and incubated for 1
h at 37 ◦C. Later, 100 µL of an HRP-streptavidin complex (AMDEX, Sigma-Aldrich, Saint
Louis, MI, USA) diluted 1:10000 was added to each well and incubated for 1 h at 37 ◦C. Six
washes with PBS-Tween-20 0.05% were done between each incubation. Finally, the reaction
was revealed adding 100 µL of a chromogenic substrate solution to each well (0.5 mg.mL−1
o-phenylenediamine (Sigma-Aldrich), 0.5 µL.mL−1 H2O2 30 vol., 50 mM citrate/phosphate
buffer, pH 5.3). The reaction was stopped adding 50 µL of a 0.5 M H2SO4 solution and the
optical density was measured at 492 nm in a plate reader spectrophotometer (Labsystems
Multiskan®).
2.7.2. Fluorescence-Based Quantification of VLP Production
The concentration of cVLPs was assessed by fluorometry using an in-house developed
and qualified quantification assay [23]. VLP containing supernatants were recovered by cell
culture centrifugation at 300 g for 5 min. Green fluorescence was measured at RT using a
Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA)
set as follows: λex = 488 nm (slit 5 nm), λem = 510 nm (slit 10 nm). Relative fluorescence unit
values (RFU) were calculated by subtracting fluorescence units (FU) values of untransfected
negative control samples. There is a linear correlation between fluorescence intensity and
p24 values determined using the INNOTEST ELISA HIV antigen mAb (Innogenetics NV,
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Gent, Belgium). RFU values can be converted to Gag-GFP concentration values using the
following equation:
Gag-GFP (ng/mL) = (3.245 × RFU) − 1.6833) × 36 (1)
where Gag-GFP is the estimated concentration of polyprotein and RFU is the measured
GFP fluorescence intensity in the samples. The first term is the correlation equation
between fluorescence values and p24 concentrations determined by ELISA, and 36 is a
correction factor that takes into account the difference in molecular weight between p24
and Gag-GFP and an underestimation arising from using the p24 ELISA to estimate p55
Gag concentrations.
2.7.3. Nanoparticle Tracking Analysis (NTA)
A NanoSight® NS300 device (Malvern Panalytical, Malvern, United Kingdom) equipped
with a blue laser module (488 nm) for fluorescent particles (Gag-GFP VLPs), and a neutral
density filter for total nanoparticle measurement using light diffraction was used. The mea-
surements were performed at Service of Preparation and Characterization of Soft Materials
(Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Cerdanyola del Vallès, Spain).
Data were analyzed with the NanoSight® NTA 3.2 software (Malvern Panalytical) and
the camera level and detection threshold were manually adjusted for each sample. Before
injection in the device chamber, samples were diluted to a final volume of 1 mL with a
nanoparticle concentration around 108 particles/mL. All measurements were performed in
triplicate and normalized by an internal control consisting of HIV-1 Gag-eGFP VLPs.
2.8. Electron Microscopy
2.8.1. Transmission Electron Microscopy (TEM)
cVLPs were adsorbed onto formvar-coated 300-mesh copper grids for 2 min. Excess
was removed with filter paper and grids were then negatively stained with 2% uranyl
acetate for 2 min. Samples were observed in a Jeol JEM-1400 (Jeol LTD, Tokyo, Japan)
TEM equipped with a CCD-multiscan camera (Model No. 895, Gatan Inc., Pleasanton, CA,
USA).
For TEM immunolabeling assays, after VLPs adsorption grids were blocked with 2%
BSA in PBS, they were then incubated with an in-house developed RVG protein specific
monoclonal antibody [22] (diluted 1:100 in PBS). Cells were washed (PBS), followed by 30
min incubation at RT with with secondary goat anti-mouse antibody (at a dilution of 1 in
25) coupled with 15 nm gold particles (15 nm, BBI Solutions, Cardiff, Wales, UK).
2.8.2. Cryogenic Electron Microscopy (CryoTEM)
cVLP morphology was studied by CryoTEM. A 2–3 µL amount of sample was blotted
onto holey carbon grids (Quantifoil Micro Tools, Großloebichau, Germany and Micro to
Nano, Haarlem, Netherlands) previously glow discharged in a PELCO easiGlow glow
discharger unit. The samples were subsequently plunged into liquid ethane at −180 ◦C
using a Leica EM GP cryo workstation and observed in a JEM 2011 electron microscope
(JEOL Ltd., Tokyo, Japan) operating at 200 kV. During imaging, samples were maintained
at −173 ◦C, and pictures were taken using a CCD-multiscan camera (Model No. 895, Gatan
Inc., Pleasanton, CA, USA).
2.9. Mice Immunization and Serology
2.9.1. Immunization Plan
The immunization protocols were approved and supervised by the Advisory Com-
mittee on Ethics and Security of the School of Biochemistry and Biological Sciences, Uni-
versidad Nacional del Litoral, according to international guidelines (“Guide for the Care
and Use of Laboratory Animals”, Eighth Edition National Research Council 2011).
Female Balb/c mice of 6–8 weeks of age (SPF, Centro de Medicina Comparada, ICIVET-
CONICET UNL, Argentina) were intramuscularly immunized with three doses at days 0,
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14 and 35. In group I (n = 7) animals were immunized with GH-RVG/Gag-GFP chimeric
VLPs (cVLPs), purified by ultracentrifugation. Each dose contained a total amount of 2.8 ×
1010 particles in 100 uL of PBS, measured by fluorometry. This corresponds to 0.24 Elisa
Units per dose of rabies glycoprotein, measured by sandwich ELISA [24]. In group II (n
= 8) mice were injected with VLPs composed only of RVG (RVG VLPs), produced as was
previously described [24,25]. For this group, each dose contained 0.24 Elisa Units of rabies
glycoprotein in 100 ul of PBS, i.e, a dose equivalent to that the given in group I. Both VLPs
were formulated with LipoSap® adjuvant with a final concentration of 100 µg/mL. This
adjuvant was commercially obtained from Lipomize S.R.L., Argentina (www.lipomize.
com.ar) and is the commercial product of an adjuvant called ISPA [26,27], which consists
of cage-like particles with low surface charge density containing Quil—A® as immune
response stimulator. This adjuvant was previously evaluated for FMDV and rabies VLPs,
as vaccine candidates [27–29]. As a control or reference, a commercial anti-FMDV vaccine
(Bioaftogen®, Biogénesis Bagó, Argentina) was injected in a third group (n = 8), with
20 µL dose per animal. Animals were bled two weeks after the last dose and the sera was
obtained and conserved at −20 ◦C until further analysis.
2.9.2. Quantification of RV Specific Immunoglobulins
96-well microplates (Greiner Bio-one, Kremsmünster, Austria) were coated with 100 µL
of an appropriate dilution of RVG-VLPs in carbonate buffer pH 9.6 for 1 h at 37 ◦C and
overnight at 4 ◦C. Plates were washed six times with PBS-Tween-20 0.05% and then blocked
with 200 µL per well of 2% skim milk in PBS for 1 h at 37 ◦C. Two-fold serial dilutions
of sera samples in skim milk 0.2%-PBS Tween-20 0.05% were incubated for 1 h at 37 ◦C.
After that, 100 µL of an HRP conjugated anti-mouse antibody (Dako, Agilent Technologies,
Santa Clara, CA, USA) diluted 1:1000 in skim milk 0.2%-PBS tween-20 0.05% was added
to each well and incubated for 1 h at 37 ◦C. A total of six washes with PBS-Tween–20
0.05% were done between each incubation. Finally, the reaction was revealed adding
100 µL of a chromogenic substrate solution to each well (0.5 mg.mL−1 o-phenylenediamine
(Sigma-Aldrich, Saint Louis, MI, USA), 0.5 µL/mL H2O2 30 vol., 50 mM citrate/phosphate
buffer, pH 5.3). The reaction was stopped adding 50 µL of a 0.5 M H2SO4 solution and the
optical density was measured at 492 nm in a plate reader spectrophotometer (Labsystems
Multiskan®). Antibody titers were calculated as the end-point serum dilution yielding an
optical density higher than the cut-off value. This cut-off was calculated as the mean + 2
S.D. of the optical density of negative controls (basal mice sera).
2.9.3. Quantification of FMD Disease Epitope Specific Immunoglobulins
96-well microplates (Polysorp®, NuncTM) were coated with 2 µg per well of a G-H
loop A/Arg/01 synthetic peptide (GSSRRGDLGSLAARVVKALPA, GenScript®, NJ, USA)
in carbonate buffer pH 9.6 for 1 h at 37 ◦C and overnight at 4 ◦C. Plates were washed six
times with PBS-Tween-20 0.05% and then blocked with 200 µL per well of 2% skim milk
in PBS for 1 h at 37 ◦C. Two-fold serial dilutions of sera samples in skim milk 0.2%-PBS
tween-20 0.05% were incubated for 1 h at 37 ◦C. After that, 100 µL of an anti-mouse rabbit
serum diluted 1:500 in skim milk 0.2%-PBS tween-20 0.05% was added to each well and
incubated for 1 h at 37 ◦C. After that, an HRP conjugated anti-rabbit antibody (Dako,
Agilent Technologies, Santa Clara, CA, USA) diluted 1:1000 in skim milk 0.2%-PBS tween-
20 0.05% was added to each well and incubated for 1 h at 37 ◦C. A total of six washes
with PBS-Tween-20 0.05% were done between each incubation. Finally, the reaction was
revealed adding 100 µL of a chromogenic substrate solution to each well (0.5 mg.mL−1
o-phenylenediamine (Sigma-Aldrich, Saint Louis, MI, USA), 0.5 µL.mL−1 H2O2 30 vol.,
50 mM citrate/phosphate buffer, pH 5.3). The reaction was stopped, adding 50 µL of a
0.5 M H2SO4 solution and the optical density was measured at 492 nm in a plate reader
spectrophotometer (Labsystems Multiskan®). Antibody titers were calculated as the end-
point serum dilution yielding an optical density higher than the cut-off value. This cut-off
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was calculated as the mean + 2 S.D. of the optical density of negative controls (basal mice
sera).
2.10. Statistical Analysis
Differences between treatments were evaluated through a one-way analysis of vari-
ance (ANOVA). When the ANOVA produced significant results (p < 0.05), a post-hoc
Tukey’s multiple comparison test was applied. All statistical analyses were performed
using GraphPad Prism for Windows, version 5.01 (GraphPad Software Inc.).
3. Results
3.1. Design, Construction and Analysis of the Expression of GH-RVG Fusion Protein
With the objective to construct a rabies fusion glycoprotein displaying the G-H loop
epitope on the surface of the cVLPs, the sequence of the corresponding 21 amino acids
was inserted in the N-term of RVG, after the signal peptide (Figure 1). This sequence was
cloned in pCiNeo plasmid, obtaining the pCiNeo-GH-RVG expression vector.
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Figure 1. GH-RVG fusion protein structure. The coding sequence of the FMDV GH loop epitope
was inserted between the glycoprotein signal peptide and the ectodomain. RVG: native rabies virus
glycoprotein.
In order to analyze if the insertion of this epitope had modified the correct expression
and the subcellular localization of the RVG protein, using pCiNeo-GH-RVG and pGag-
EGFP plasmids, we performed a co-transfection of HEK293 cells. At 72 hpt, we analyzed
the cells by standard confocal laser scanning microscopy (CLSM). As can be seen in Figure
2, the fluorescence corresponding to the anti-rabies antibody immunostaining was detected
on the cell surface (Figure 2C), showing that GH-RVG is anchored in the plasma membrane,
as xpected for the rabies glycoprotein [30]. On the other hand, when GH-RVG was co-
expressed with Gag-GFP we observed a clear overlapping of th signals, matching cell
membra e staining signal (Figure 2D,E). These results showed that both c imeric pro eins
are found in th plasma membrane of the cell, from wh re VLPs bud to the sup rnatant [31].
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Figure 2. GH-RVG fusion protein expression analysis. HEK293 cells were co-transfected with GH-
RVG and Gag-GFP vectors, and 72 hpt were incubated with an in-house developed RVG specific
monoclonal antibody, followed by an incubation ith an AlexaFluor647® conjugated anti-mouse
secondary ant bo y (magenta). Lipid membran was st ined with CellMask™ (red) and cell nucleus
was stained with Hoechst (blue). The green signal corresponds to Gag-eGFP (B) and D is the merge
of the four channels. (A–D): Standard confocal laser scanning microscopy. (E): Fluorescence intensity
though the diameter of the cell is represented with a histogram performed with FIJI (Image J) software.
Green line corresponds to GagGFP, red line to the CellMask staining and the blue line correspond
to the fluorescence intensity obtained with the immunolabeling of the cells (AlexaFluor647). (F,G):
Super-resolution fluorescence microscopy. (F): expression of GH-RVG fusion glycoprotein alone. (G):
Co-expression of GH-RVG and Gag-GFP fusion proteins.
Later, these observations were confirmed by super-resolution fluorescence microscopy
(SRFM). With this novel technique higher resolutions are obtained when viral chimeric
protein are analyzed, both within the cell during VLP budding or at the single particle
analysis [15]. We could clearly observe how GH-RVG fusion protein is exposed in the
outer part of the transfected cell while Gag-GFP is associated with the inner part of the
plasma membrane (Figure 2F,G). In addition, GH-RVG protein is concentrated in clusters
throughout the cell surface, presumably associated with lipid rafts, as described for the
rabies glycoprotein and other viral membrane proteins [32,33]. These results demonstrated
that the insertion of the GH-loop epitope within the RVG sequence did not alter the normal
pathway for the expression of this glycoprotein or its folding.
Next, we investigated if in the context of the GH-RVG fusion protein, the foot-and-
mouth disease virus (FMDV) epitope was correctly exposed to the liquid surrounding,
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and able to be recognized by specific antibodies. To study this, cells transfected only with
GH-RVG vector were immunostained with a polyclonal antibody specific for FMDV, and
analyzed by flow cytometry and SCLM (Figure 3A,B). As can be seen in Figure 3A, 72 hpt,
the heterologous epitope present in GH-RVG fusion protein, was able to be detected by
specific antibodies (marker 2). In addition, when cells were observed in SCLM (Figure 3B),
the specific fluorescence was detected on the cell surface, as was previously observed when
cells were analyzed with anti-rabies antibodies. This result is of paramount importance
since we hypothesized that, if this chimeric protein is able to correctly expose the GH-loop
epitope, being able to interact with anti-FMDV antibodies in solution, it might also be able
to induce the production of anti-epitope antibodies when injected as an immunogen. This
interpretation was later confirmed in this work.
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Figure 3. G–H loop epitope detection. A–B: HEK293 cells were transfected with GH-RVG vector and, 72 hpt, cells
were incubated with an in-house developed FMDV specific polyclonal antibody, followed by an incubation with an
AlexaFluor488® conjugated anti-rabbit secondary antibody. (A): Flow cytometry. Marker 1 represents negative cells and
marker 2 and 3 the positive cells. (B): Confocal microscopy. (C): HEK293 were co-transfected with GH-RVG and Gag-GFP
vectors, and 72 hpt cVLPs were harvested and purified by ultracentrifugation. The exposition of the GH loop epitope in this
VLPs sample was analyzed by bi-specific ELISA: cVLPs were captured using a FMDV specific serum and the detection was
performed using an anti-RV antibody. As controls, we used c lture medium of wild type HEK293 cells and VLPs containing
wild type RVG (without the FMDV epitope). Results are expressed as mean ± SD (n = 3).
3.2. cVLP Expression and Characterization
Once the correct expression and subcellular localization of the GH-RVG fusion protein
was confirmed, we analyzed the budding of cVLPs when HEK293 cells are co-transfected
with both chimeric viral proteins, the HIV-1 Gag protein fused to the GFP and the GH-RVG.
At 72 hpt, culture medium was harvested and the hydrodynamic diameter and particle
size distribution of cVLPs were studied by nanoparticle tracking analysis (NTA) (Figure 4).
Generally, NTA is a technique that detects and measures all particles present in the
sample, where host cell debris and other extracellular particles can affect the correct size
measurement of VLPs [34]. To overcome this problem, in this work, cVLPs were analyzed
using a blue laser module, where only fluorescent particles (GFP positive) were quantified,
obtaining an average value of 130 ± 40 nm with a particle size distribution similar to that
previously described for Gag-based VLPs (Figure 4) [15].
Further, cVLPs were purified by ultracentrifugation and their morphology was an-
alyzed by transmission electron microscopy (TEM) and cryogenic electron microscopy
(Cryo-TEM). As can be seen in Figure 5A,B, we observed enveloped spherical electrodense
nanoparticles, as was previously described for GFP-Gag-based VLPs [15,35,36].
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centrifugation, before morphology analysis. (A): TEM of purified cVLPs. (B): CryoTEM. (C,D): Gold-
immunolabeled TEM. Grids were incubated with a RVG protein specific monoclonal antibody, followed
by an incubation a with secondary goat anti-mouse antibody coupled with 15 nm gold particles.
On the other hand, we investigated if the fusion protein GH-RVG was present in
the structure of the observed particles, anchored in the VLPs envelope as is described
when a membrane glycoprotein is co-expressed with Gag protein [37–40]. Therfore, we
performed immunogold labelling of the purified cVLPs and analyzed it by TEM (Figure
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5C,D). As can be observed in two individual fields, gold nanoparticles were detected
surrounding the cVLP, specifically linked to the particle lipid membrane, revealing that
the rabies chimeric fusion glycoprotein is exposed on the pseudoviral particles surface, as
expected. In addition, in order to confirm if the G-H loop epitope was exposed on the VLPs
and is able to be recognized by antibodies in solution, a preparation of purified cVLPs was
analyzed by a bi-functional ELISA assay (Figure 3C). In this assay, VLPs were captured
using a FMDV specific serum and the detection was performed using an anti-RV antibody.
As can be seen in Figure 3C, a specific signal was detected in the cVLPs sample when
compared with the controls, which means that in the context of this chimeric VLP, the G-H
loop epitope is exposed and available to be recognized and bound by specific anti-FMDV
antibodies.
3.3. cVLPs Production Optimization
The addition of valproic acid and caffeine increases cell viability and VLPs production
of HIV-1 Gag based VLPs in HEK293 suspension cell cultures by 3.8-fold, as demonstrated
previously [41]. In this work, we evaluated if these additives have the same positive
effect in the expression of the rabies fusion protein and in the production of Gag VLPs
functionalized with this envelope glycoprotein.
With this aim, we performed single (GH-RVG only) and double transfections (GH-
RVG + Gag-GFP) of HEK239 cells and 4 hpt valproic acid and caffeine were added to
the culture medium. On the one hand, 72 hpt cells were analyzed by flow cytometry in
order to measure the percentage of GH-RVG positive cells (Figure 6A) or double positive
cells (Figure 6B), both with or without additives. We observed that the expression level
was increased by four-fold when additives were present in the culture medium after
transfection.
These results show that caffeine and valproic acid have the same positive effect on the
expression of the fusion glycoprotein than on the expression of Gag-GFP, as it has been
previously reported [17,41]. On the other hand, we studied the effect of these additives
on the concentration of cVLPs secreted (Figure 6B). As can be seen, additives have a clear
positive effect on cVLPs production and budding, from the first 24 hpt through all the
time period studied. Further, at 96 hpt, a culture without additives presented a particle
concentration of 5.2 × 109 VLPs/mL while when valproic acid and caffeine were added,
we obtained a concentration of 2.9 × 1010 VLPs/mL, a 5.5-fold increase.
3.4. Evaluation of cVLPs Immunogenicity in Mice
Finally, after characterization of the constructed fusion glycoprotein and chimeric
VLPs, confirming that the heterologous FMDV epitope was correctly expressed and ex-
posed on the particle surface, we investigated if these cVLPs were able to induce a specific
immune response against the G-H loop. Thus, we vaccinated mice with three successive
doses of purified VLPs and, 15 days after the third dose, sera were obtained to analyze
the humoral immune response triggered. First, anti-rabies immunoglobulins titer was
quantified by indirect ELISA (Figure 7A), observing that mice injected with the cVLPs pre-
sented a titer comparable to that obtained in the group vaccinated with rabies VLPs (RV-G
VLPs). This result showed that, although the primary structure of RVG was genetically
modified by adding the G-H loop epitope, the GH-RVG fusion protein present in the cVLPs
is still able to induce specific anti-rabies antibodies. Secondly, and more importantly, we
analyzed the induction of antibodies against the heterologous FMDV epitope, performing
an indirect ELISA developed to this aim. As can be seen in Figure 7B, when mice were
injected with the cVLPs, specific anti-G-H loop antibodies were detected and quantified,
with no statistical differences with the titer triggered by a commercial FMDV vaccine.
In addition, no antibodies were detected in the group of mice injected with RV-G VLPs,
demonstrating that this ELISA assay was efficient to detect only anti-GH loop antibodies.
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Figure 6. cVLPs production optimization. HEK293 cells were transfected with GH-RVG (A) or co-
transfected with GH-RVG and ag-GFP vectors (B), and 4 hpt valproic acid and caffeine (additives)
were added to the culture, wh n correspond. 72 hpt cells er harvested a incuba ed with an in-
house developed RVG specific monoclonal antibody, followed by an incubation with an AlexaFluor647®
conjugated anti-mouse secondary antibody. Finally, immunostained cells were analyzed by flow
cytometry. (C): Medium culture of transfected cells was harvested each 24 h and cVLPs concentration
was quantified by fluorometry. A single transfection with Gag-GFP alone was performed as a control,
with additives. Results are expressed as mean ± SD (n = 3). ** p < 0.01. *** p < 0.001.
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Two control groups were injected with rabies VLPs (RV-G VLPs) or a commercial FMDV vaccine (n = 8), following the same
immunization protocol. Sera was obtained 15 days after the third dose and analyzed for (A): anti rabies specific antibodies, by indirect
ELISA. (B): anti GH-loop FMDV epitope specific antibodies, by indirect ELISA using a synthetic peptide to coat the plates. Antibody
titers were calculated as the end-point serum dilution yielding an optical density higher than the cut-off value. This cut-off was
calculated as the mean + 2 S.D. of the optical density of negative controls (basal mice sera). Results are expressed as the individual titer
values for each animal (dots) and the median of each group. N/D: not detectable.
These results demonstrated that the FMDV epitope present in the GH-RVG fusion
protein is able to interact with the B cells receptors of the vaccinated animals, and induce
the production of specific antibodies. Nevertheless, more experiments should be performed
in order to study in more detail the immune response triggered.
4. Discussion
Foot-and-mouth disease is a viral relevant disease, both for animal health and for its
economic impact, with the potential of producing millions of losses in livestock production.
Currently, the main strategy to control the disease in endemic countries are mandatory
vaccination campaigns, using inactivated viral vaccines [4,6,42,43]. Although these vac-
cines have been shown to be effective, the increment of worldwide trade, together with
fast population growth, international travel and migration may contribute to the disease
resurgence, even in countries where the disease is controlled without vaccination. This
scenario will challenge the capabilities of the available vaccines triggering the need for
improved vaccines against FMDV. New generation vaccine candidates, based on recombi-
nant technologies, should play a central role in the search for improved FMDV vaccines,
with higher potency, safety and DIVA (differentiating infected from vaccinated animals)
characteristics [44].
Virus-like particles have been widely used for vaccine development in the last decades.
Several VLP-based vaccines are commercially available for human use, including Human
Papilloma Virus, Hepatitis B virus and, more recently, the first VLP-based malaria vaccine
Mosquirix® has been approved in Europe [8,11,45–48]. On the other hand, VLPs are being
taken into account as potential immunogens for veterinary vaccines [49–52].
In this work, we described the development and analysis of a chimeric VLP-based
vaccine candidate for FMDV, based on the co-expression, in HEK293 cells, of the HIV-1
Gag protein and a novel fusion rabies glycoprotein, that carries in its N-term the FMDV
main antigen: the G-H loop (Figure 1). The main goal was to take advantage of the well
stablished Gag polyprotein platform [16], together with optimized transient transfection
techniques [17,41], in order to produce VLPs functionalized with the chimeric fusion
protein (GH-RVG).
As a first step, we evaluated the cellular expression of GH-RVG by flow cytometry
and confocal microscopy, demonstrating that the genetic fusion of G-H loop did not alter
the correct sub-cellular localization of the native RVG (Figure 2). In addition, using new
generation super-resolution imaging techniques, we showed that GH-RVG is localized in
the plasma membrane of the transfected cells, concentrated in clusters, with the normal
pattern described for this Rhabdovirus glycoprotein [32,33]. Further, when GH-RVG is co-
expressed with Gag-GFP, co-localization of both proteins in the cell external membrane was
observed (Figure 2). This result is crucial for the understanding of the cVLP budding pro-
cess, as was recently described for naked Gag-GFP particles formation [35]. In this case, the
merge of the three staining markers (magenta for GH-RVG, red for plasma membrane and
green for Gag-GFP; Figure 2) shed us light on these functionalized VLPs morphogenesis,
demonstrating that the pseudovirus particle assembly occurs in the cell plasma membrane.
More importantly, performing immunostainings with a FMDV hyperimmune serum, we
showed that the heterologous antigenic site, genetically fused to RVG, is available to be
recognized by specific G-H loop antibodies (Figure 3A,B).
Later, we analyzed the cVLPs production when HEK293 are transfected with both
viral proteins sequences, GH-RVG and Gag-GFP. First, by NTA, we analyzed the particle
size distribution of cVLPs in the culture medium and calculated a hydrodynamic diameter
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of 130 ± 40 nm (Figure 4). After that, cVLPs were purified by ultracentrifugation and
studied by TEM and Cryo-TEM. Spherical pseudo-viral particles were detected, carrying an
envelope membrane that efficiently display the fusion glycoprotein on its surface (Figure
5). Additionally, we confirmed that the cVLPs are able to expose the G-H loop to the liquid
surrounding when analyzed by specific ELISA (Figure 3B).
Further, to obtain the proof-of-concept of these cVLPs as a FMDV vaccine candidate,
we evaluated the immunogenicity of these chimeric particles in experimental animals.
After immunizing mice with three successive doses at days 0, 14 and 35 (2.8 × 1010 VLPs
per dose), we confirmed that these cVLPs are able to induce a specific humoral immune
response based on antibodies directed to the G-H loop (Figure 7B), a key result showing
that this FMDV domain is available to be recognized by the B cells receptors. Anti G-H loop
antibodies have been proven to be the main responsible of FMDV neutralization and, thus,
generate protection against virus infection [2,43,53,54]. Although these are preliminary
results, they are very promising and encourage further studies to deeply characterize the
immune response induced by these novel cVLPs, analyze the cellular response triggered as
well and evaluate if it is able to protect animals from a virus challenge.
An interesting feature of this cVLPs is that they are able to trigger anti-rabies an-
tibodies production (Figure 7A), together with the already discussed G-H loop specific
antibodies. This is important considering that rabies and FMD are important zoonotic
diseases that affect cattle, and the vaccination against these viruses are both mandatory
in many countries, with annual re-vaccination schedules [5,55]. The possibility to have
a vaccine that protect animals for both infections could be a good approach in order to
reduce the overall vaccine price and simplify the vaccination logistics.
On the other hand, we worked on the bioprocess optimization in order to increase the
cVLPs productivity. Applying a previously developed methodology for the improvement
of Gag-GFP VLPs [19,41], we obtained a 5.5-fold increase in the VLPs yield (Figure 6).
These results are of paramount importance considering that one of the main goals in the
development of a vaccine candidate is the reduction for producing a vaccine dose. This
becomes even more important when the vaccine is for veterinary applications, where prices
are low and the achievements in the optimization of the process would have a higher impact.
Furthermore, this TGE technique can be applied not only in batch and fed-batch processes,
but to continuous VLPs production in bioreactor with perfusion, offering a platform for
the future process development and scale up of this vaccine candidate production [56,57].
In any event, it is important to be aware that TGE present several challenges for its
scaling-up process, including the large-scale high-quality DNA production and the need
to prepare the DNA/polyplexes before their addition into the bioreactor, where large
volume manipulation can cause delays in complex formation, impacting on the complex
size distribution and, consequently, on the transfection efficiency. In addition, some TGE
procedures include a medium exchange step, whereby scaling-up this is labor-intensive
and associated with potential contamination risk. Nevertheless, in the last few years, great
advances have been achieved in this field [20], which allow us to propose this culture
platform for the production of a novel FMDV vaccine candidate.
In conclusion, we consider that the results presented in this work represent a valid
approach to the development of a novel recombinant FMDV vaccine candidate, avoiding
virus manipulation during production, with no requirement for viral contention facilities.
Furthermore, the results also show the capacity of Gag-VLPs as a platform to incorporate
antigens from unrelated diseases. This enables the use of the already developed and opti-
mized bioprocess for the Gag-VLP production to give a rapid response to emerging diseases
or pandemic outbreaks only co-transfecting with the desired epitope. Additionally, in this
work, we have demonstrated the easy production of the Gag-based VLPs pseudotyped
with the GH-RVG fusion protein carrying the A/Arg/01 G-H loop serotype. As the FMDV
has seven serotypes and the approved vaccines normally comprises two, three or four
serotypes (depending on the country), this platform could be used to produce it in an easier
manner (by co-transfecting with the plasmids encoding for the epitopes of the desired
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serotypes) than the actual production system based on the inactivated virus in which the
different serotypes need to be produced separately, inactivated and mixed for the final
vaccine.
Concluding, these results encourage further studies to characterize the immune re-
sponse triggered by these cVLPs and to work in the scaling-up process to evaluate the
productivities that can be obtained.
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